Pharmaceutical and life sciences companies continue to analyze the impact of the new revenue guidance on their contracts, accounting policies, and financial statements. This publication reflects implementation developments since issuance of the standards and highlights considerations in evaluating their impact on revenue arrangements common to pharmaceutical and life sciences companies.
© 2016 - 2019 PwC. All rights reserved. PwC refers to the US member firm or one of its subsidiaries or affiliates, and may sometimes refer to the PwC network. Each member firm is a separate legal entity. Please see www.pwc.com/structure for further details.